EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Pruritus - Pipeline Review, H1 2015

  • ID: 3150113
  • Report
  • February 2015
  • 91 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AlbireoPharma
  • Cara Therapeutics, Inc.
  • Creabilis SA
  • FAES Farma SA
  • Helsinn Holding S.A.
  • LEO Pharma A/S
  • MORE
Pruritus - Pipeline Review, H1 2015

Summary

This, ‘Pruritus - Pipeline Review, H1 2015’, provides an overview of the Pruritus’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pruritus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pruritus and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pruritus
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pruritus and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pruritus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pruritus pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pruritus
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AlbireoPharma
  • Cara Therapeutics, Inc.
  • Creabilis SA
  • FAES Farma SA
  • Helsinn Holding S.A.
  • LEO Pharma A/S
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Pruritus Overview
Therapeutics Development
Pipeline Products for Pruritus - Overview
Pipeline Products for Pruritus - Comparative Analysis
Pruritus - Therapeutics under Development by Companies
Pruritus - Therapeutics under Investigation by Universities/Institutes
Pruritus - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Pruritus - Products under Development by Companies
Pruritus - Products under Investigation by Universities/Institutes
Pruritus - Companies Involved in Therapeutics Development
AlbireoPharma
Amorepacific Corporation
Cara Therapeutics, Inc.
Conrig Pharma ApS
Creabilis SA
ELORAC, Inc.
FAES Farma SA
GlaxoSmithKline plc
Helsinn Holding S.A.
Hydra Biosciences, Inc.
LEO Pharma A/S
Merck & Co., Inc.
NeRRe Therapeutics Ltd
Nippon Shinyaku Co., Ltd.
RDD Pharma Ltd.
Shionogi & Co., Ltd.
Tioga Pharmaceuticals, Inc.
Trevi Therapeutics, Inc.
Vanda Pharmaceuticals Inc.
Pruritus - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-4250 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aprepitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
asimadoline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASN-008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bilastine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-746 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR-845 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CRG-010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CT-327 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
desloratadine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Target Mas-Related G-Protein Coupled Receptor for Pruritus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2330672 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nalbuphine hydrochloride ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
naloxone hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
netupitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NS-141 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
orvepitant maleate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PAC-14028 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PP-120 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
serlopitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Pruritus Ani - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Agonize CB2 for Pruritus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Block NaV1.7 Channel for Pain and Pruritus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tradipitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pruritus - Recent Pipeline Updates
Pruritus - Dormant Projects
Pruritus - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Pruritus, H1 2015
Number of Products under Development for Pruritus - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Pruritus - Pipeline by AlbireoPharma, H1 2015
Pruritus - Pipeline by Amorepacific Corporation, H1 2015
Pruritus - Pipeline by Cara Therapeutics, Inc., H1 2015
Pruritus - Pipeline by Conrig Pharma ApS, H1 2015
Pruritus - Pipeline by Creabilis SA, H1 2015
Pruritus - Pipeline by ELORAC, Inc., H1 2015
Pruritus - Pipeline by FAES Farma SA, H1 2015
Pruritus - Pipeline by GlaxoSmithKline plc, H1 2015
Pruritus - Pipeline by Helsinn Holding S.A., H1 2015
Pruritus - Pipeline by Hydra Biosciences, Inc., H1 2015
Pruritus - Pipeline by LEO Pharma A/S, H1 2015
Pruritus - Pipeline by Merck & Co., Inc., H1 2015
Pruritus - Pipeline by NeRRe Therapeutics Ltd, H1 2015
Pruritus - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015
Pruritus - Pipeline by RDD Pharma Ltd., H1 2015
Pruritus - Pipeline by Shionogi & Co., Ltd., H1 2015
Pruritus - Pipeline by Tioga Pharmaceuticals, Inc., H1 2015
Pruritus - Pipeline by Trevi Therapeutics, Inc., H1 2015
Pruritus - Pipeline by Vanda Pharmaceuticals Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Pruritus Therapeutics - Recent Pipeline Updates, H1 2015
Pruritus - Dormant Projects, H1 2015
Pruritus - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Pruritus, H1 2015
Number of Products under Development for Pruritus - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
- AlbireoPharma
- Amorepacific Corporation
- Cara Therapeutics, Inc.
- Conrig Pharma ApS
- Creabilis SA
- ELORAC, Inc.
- FAES Farma SA
- GlaxoSmithKline plc
- Helsinn Holding S.A.
- Hydra Biosciences, Inc.
- LEO Pharma A/S
- Merck & Co., Inc.
- NeRRe Therapeutics Ltd
- Nippon Shinyaku Co., Ltd.
- RDD Pharma Ltd.
- Shionogi & Co., Ltd.
- Tioga Pharmaceuticals, Inc.
- Trevi Therapeutics, Inc.
- Vanda Pharmaceuticals Inc.
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll